A medication impregnated bone cement (MIBC) coated intramedullary (IM) nail for fixation of a long bone fracture comprising an IM nail base and medication impregnated bone cement. The bone cement encapsulates at least a portion of the IM nail base and forms an interface between the adjacent surfaces of the IM nail base and the bone cement. The interface between the encapsulating bone cement and the encapsulated IM nail base being enhanced to increase the adhesion of the encapsulating bone cement to the encapsulated IM nail base. The increase in adhesion being sufficient to ensure that the encapsulating bone cement remains adhered to the encapsulated IM nail base when the medication impregnated bone cement coated intramedullary nail is removed from the long bone.

A bandage to control bleeding from an open wound has a hemostatic gauze. An absorbent pad is removably attached to the hemostatic gauze.

A hemostatic composition is provided. The hemostatic composition includes a hemostatically effective amount of a hemostatic agent that includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle. Also provided are medical devices and methods of use to promote blood clotting.

Advantageously, para-chloroaniline (PCA) is minimal in antimicrobial articles prepared according to the method of the invention. A method of forming an antimicrobial article according to the invention comprises steps of: providing a polymerizable composition; incorporating an antimicrobially effective amount of at least one chlorhexidine-containing antimicrobial agent into the polymerizable composition; and, polymerizing the polymerizable composition to form chlorhexidine-containing polymer of the antimicrobial article, wherein processing temperature during the method is less than about 80° C.

Disclosed herein are compositions to use in biofouling-resistant coatings, biofouling-resistant coatings, methods of making biofouling-resistant coatings, biofouling-resistant devices, and methods of making biofouling-resistant devices.

The present invention provides a controlled release formulation comprising a silicone substrate which comprises a compound of Formula (I): AA-AA-AA-X—Y. The invention further provides methods of making these formulations, medical devices such as dressings incorporating said formulations and medical uses thereof.

Provided is a method for preventing the disturbance of vaginal bacterial flora during the menstrual period and improving the vaginal bacterial flora. One aspect of the present invention is a sanitary product carrying lactoferrin or a composition comprising lactoferrin and an auxiliary substance. Also provided is a kit comprising a sanitary product, and lactoferrin or the composition comprising lactoferrin and an auxiliary substance.

Provided herein are fatty-ammonium salt/starch inclusion complexes comprising one or more of a variety of fatty amines. Such complexes can be combined with film-forming agents, such as poly(vinyl) alcohol (PVOH) and plasticizing agents. The inclusion complexes of the present invention can be utilized as antimicrobial agents, preventing microbial growth on organic and inorganic surfaces. In specific embodiments, inclusion complexes of the present invention are applied to vegetable or fruit surfaces in order to impede microbial growth. Inclusion complexes of the present invention can be applied to wood in order to impede microbial growth and insect consumption and to wound dressings.

Disclosed herein are synthetic hydrogels suitable for delivering antimicrobial proteins, optionally in combination with bone regenerating agents to injured tissues. The hydrogels can include lysostaphin and one or more bone morphogenic proteins. The hydrogels are composed of a network of crosslinked hydrophilic polymers and adhesion peptides.

A method of corneal implantation with cross-linking is disclosed herein. In one or more embodiments, the method includes the steps of: (i) prior to implantation, treating an implant formed from donor corneal tissue or a tissue culture grown corneal stroma with a solution of sodium dodecyl sulfate (SDS), Triton X-100, benzalkonium chloride (BAK), Igepal, genipin, 100% glycerol, or alcohol for making the implant acellular, and for killing any bacteria, viruses, or parasites prior to implantation; (ii) implanting the implant into a recipient cornea; (iii) applying laser energy to the implant so as to modify the refractive power of the implant while being monitored using a Shack-Hartmann wavefront system so as to achieve a desired refractive power for the implant; and (iv) applying a cross-linking solution and irradiating the implant to cross-link the implant to prevent an immune response to the implant and/or rejection of the implant by a patient.